share_log

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

Benzinga ·  Nov 8, 2023 19:19

Chardan Capital analyst Keay Nakae upgrades ProQR Therapeutics (NASDAQ:PRQR) from Neutral to Buy and announces $2 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment